Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
In this Issue Sergey Brin Bets $15M on Ibogaine Startup Soneira, But Questions Loom Over Patents Head-to-Head Trial Hopes to Assess Role of Psychotherapy in
In this Issue California’s Psychedelic Research Bottleneck Ends Today Letter to the Editor: Neşe Devenot A Look at Complaints as Oregon Psilocybin Services Turns One
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
In this Issue Lykos Insiders, Affiliates, Respond to Critics Might FDA Miss Its August 11th Goal Date? FDA-Affiliated Workshop Discusses Ketamine’s Use In Mental Health
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
Facilitator Licensing & Training DORA’s first set of rules, released in April, mark the first rules for Colorado’s regulated Natural Medicine program to become official.
In this Issue Dan Crenshaw and Elon Musk Add Fuel to Lykos ‘Dumpster Fire’ Drama ‘They Not Like Us’ — Psychedelic Drug Developers Emphasise Avoidance
Hardman: So you originally were focusing on Sweden, but now you have broadened that remit to Europe generally, if I’m understanding correctly. In terms of
In this Issue Phase 2 Study of Oral Ketamine for Depression Lauded by Media and Sponsor, Yet Closer Look Reveals Underwhelming Results UN World Drug